Last Friday I told you about the FDA’s “watch list.” It can be a sham. And it usually amounts to nothing more than a slap on the wrist for the drug company. This appears true with Celexa, a [...]
Last Friday I told you about the FDA’s “watch list.” It can be a sham. And it usually amounts to nothing more than a slap on the wrist for the drug company. This appears true with Celexa, a [...]